BRIC
View Older Stories View More Recent Stories
-
Senate bill takes first step in recognizing buildings as infrastructure
-
Theo Croker Announces New Album BLK2LIFE || A FUTURE PAST Ft. Wyclef Jean, Ari Lennox, Malaya, Kassa Overall, And More Available September 24 - Preorder Now
-
Brickworks North America Corporation Expands Direct Distribution Network with the Acquisition of The Largest Independent Brick Distributor in the U.S.
-
Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021
-
Crédit Agricole Normandie Seine : fiches descriptives de caisses locales
-
Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter’s Option to Purchase Additional Shares
-
Brickson Diamond Joins Gentreo's Board to Generate New Partnerships and Uncover Exceptional Diverse Talent
-
Baker Hughes Company Announces Second Quarter 2021 Results
-
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million
-
Brickell Biotech (BBI) Announces $5 Million Bought Deal Offering of Common Stock
-
Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock
-
Brickell Biotech to Participate at William Blair’s Biotech Focus Conference 2021
-
Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Ge
-
Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan
-
Black Resilience in Colorado Fund Marks First Year Milestone
-
Black Resilience in Colorado Fund Marks First Year Milestone
-
Brickell Biotech (BBI) Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% in the Journal of Dermatology
-
Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
-
Brickworks Opens New North American Supply Center
-
Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
Analysis: India's prized investment grade status hanging by a thread
-
Brickstone Partners Acquires Landmark, Stone Creek Apartments
-
Brickyard Opens Its Doors in Chantilly, VA
-
Ebix (EBIX) Adds Priyanka Kaul to Board
-
Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021
-
Brickell Biotech (BBI) Reports Complete Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel
-
Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
-
Brick and Mortar Businesses have been Hit Hard by the Pandemic, making E-commerce more Important than ever
-
Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis
-
Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE
-
Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology
-
Brick passe au vert pour célébrer le Jour de la Terre 2021
-
Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology
-
BRICS is bringing the power of choice to Africa
-
Chief Enterprises Releases New 12-Cavity Sealed Power Distribution Module
-
BRICS development bank approves $1 billion loan for Russia's frontline health workers
-
Bricks 4 Kidz Awarded The Best Products for Elementary Kids – 2021 by Parents' Picks Awards!
-
IBHS Chief urges Congress to champion resilience and climate adaptation for all
-
Bricz named Körber Partner of the Year for Supply Chain at Elevate Americas 2021
-
Green Business Certification Inc. Announces 2021 Board of Directors
-
Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
-
Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market
-
Brickell Biotech to Participate in March Virtual Investor Conferences
-
Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021
-
BrickBio Creates Novel Class of Bispecific Antibody Drug Conjugate and Receives Green Light on Next Phase of Therapeutic Deal with Large Pharma Partner
-
Brickell Biotech (BBI) Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% in the Journal of Dermatology
-
Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
-
BrickBio Spins Out EnCapsid: A Novel Gene Therapy Company that Creates Novel AAVs and Enables More Efficient, CRISPR Cas-9 Delivery
-
BrickBio Enters into Antibody Drug Conjugate (ADC) Co-Development Partnership with a Large Pharmaceutical Company
-
Brick Oven Manufacturer Marra Forni Appoints New Representation in Florida

